IMCD showcases patient-centric pharmaceutical solutions at CPHI Frankfurt 2025

The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile

Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer

Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population

Bajaj Healthcare posts Q2 FY26 PAT at Rs. 11.10 Cr

Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025

RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr

RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025

Roche’s Elecsys pTau181 becomes first FDA-cleared blood test to rule out Alzheimer’s pathology in primary care

New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency

AstraZeneca to lower cost of medicines for American patients

AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing

Bayer and Kumquat initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors

First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention

IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President